Reevaluating the concept of treating experimental tumors with a mixed bacterial vaccine: Coley's toxin

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Maletzki, C ^a   Klier, U ^a   Obst, W ^b   Kreikemeyer, B ^b   Linnebacher, M ^a  

^a Section of Molecular Oncology and Immunotherapy   (Germany)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CASPASE 3; CASPASE 7; COLEY'S TOXIN; COMPLEMENTARY DNA; DNA; MESSENGER RNA; PROTEIN P21; PROTEIN P21 WAF; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; BACTERIAL TOXIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; INTERLEUKIN 2 RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CD25+ T LYMPHOCYTE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG TOLERABILITY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ANALYSIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SERRATIA MARCESCENS; STREPTOCOCCUS PYOGENES; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CYCLE; CELL CYCLE CHECKPOINT; CELL GROWTH; CELL SURVIVAL; DRUG EFFECT; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PANCREAS TUMOR; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; BACTERIAL TOXINS; BACTERIAL VACCINES; CASPASE 3; CASPASE 7; CELL CYCLE; CELL CYCLE CHECKPOINTS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKOCYTES; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; RNA, MESSENGER; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 84871399268     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/230625     Document Type: Article

References (39)

1. Zacharski L. R., Sukhatme V. P., Coley's toxin revisited: immunotherapy or plasminogen activator therapy of cancer? Journal of Thrombosis and Haemostasis 2005 3 3 424 427 2-s2.0-23944458657 10.1111/j.1538-7836.2005.01110.x (Pubitemid 41632862)
2. Wiemann B., Starnes C. O., Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacology and Therapeutics 1994 64 3 529 564 2-s2.0-0028081705 10.1016/0163-7258(94)90023-X (Pubitemid 24381235)
3. Kumar H., Kawai T., Akira S., Pathogen recognition by the innate immune system. International Reviews of Immunology 2011 30 1 16 34 2-s2.0-78751560494 10.3109/08830185.2010.529976
4. Rossol M., Heine H., Meusch U., Quandt D., Klein C., Sweet M. J., Hauschildt S., LPS-induced cytokine production in human monocytes and macrophages. Critical Reviews in Immunology 2011 31 5 379 446 2-s2.0-84857061006
5. Hobohm U., Stanford J. L., Grange J. M., Pathogen-associated molecular pattern in cancer immunotherapy. Critical Reviews in Immunology 2008 28 2 95 107 2-s2.0-41949085954 (Pubitemid 351507428)
6. Skitzki J. J., Repasky E. A., Evans S. S., Hyperthermia as an immunotherapy strategy for cancer. Current Opinion in Investigational Drugs 2009 10 6 550 558 2-s2.0-67650678431
7. Oblak A., Jerala R., Toll-like receptor 4 activation in cancer progression and therapy. Clinical and Developmental Immunology 2011 2011 12 609579 2-s2.0-83455221361 10.1155/2011/609579
8. Hobohm U., Fever and cancer in perspective. Cancer Immunology, Immunotherapy 2001 50 8 391 396 2-s2.0-0034754259 (Pubitemid 33027983)
9. Nauts H. C., McLaren J. R., Coley toxins-the first century. Advances in Experimental Medicine and Biology 1990 267 483 500 2-s2.0-0025561482
10. Belardelli F., Ferrantini M., Proietti E., Kirkwood J. M., Interferon-alpha in tumor immunity and immunotherapy. Cytokine and Growth Factor Reviews 2002 13 2 119 134 2-s2.0-0036005886 10.1016/S1359-6101(01)00022-3 (Pubitemid 34229387)
11. Petrella T., Quirt I., Verma S., Single-agent interleukin-2 in the treatment of metastatic melanoma. Current Oncology 2007 14 1 21 26 2-s2.0-51649117346 10.3747/co.2007.97
12. Perabo F. G. E., Müller S. C., Current and new strategies in immunotherapy for superficial bladder cancer. Urology 2004 64 3 409 421 2-s2.0-4444323756 10.1016/j.urology.2004.04.026 (Pubitemid 39200724)
13. Klier U., Maletzki C., Göttmann N., Kreikemeyer B., Linnebacher M., Avitalized bacteria mediate tumor growth control via activation of innate immunity. Cellular Immunology 2011 269 2 120 127 2-s2.0-79957651432 10.1016/j.cellimm.2011.03.014
14. Neuzillet C., Sauvanet A., Hammel P., Prognostic factors for resectable pancreatic adenocarcinoma. Journal of visceral surgery 2011 148 4 e232 243 2-s2.0-80555139012
15. Heinrich S., Pestalozzi B., Lesurtel M., Berrevoet F., Laurent S., Delpero J. R., Raoul J. L., Bachellier P., Dufour P., Moehler M., Weber A., Lang H., Rogiers X., Clavien P. A., Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer 2011 10 11 346
16. Maletzki C., Linnebacher M., Kreikemeyer B., Emmrich J., Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut 2008 57 4 483 491 2-s2.0-41149145055 10.1136/gut.2007.125419 (Pubitemid 351442532)
17. Linnebacher M., Maletzki C., Emmrich J., Kreikemeyer B., Lysates of S. pyogenes serotype M49 induce pancreatic tumor growth delay by specific and unspecific antitumor immune responses. Journal of Immunotherapy 2008 31 8 704 713 2-s2.0-59849119193 10.1097/CJI.0b013e3181829f62
18. Hobohm U., Fever therapy revisited. British Journal of Cancer 2005 92 3 421 425 2-s2.0-15244351782 10.1038/sj.bjc.6602386 (Pubitemid 40395520)
19. Klenk M., Nakata M., Podbielski A., Skupin B., Schroten H., Kreikemeyer B., Streptococcus pyogenes serotype-dependent and independent changes in infected HEp-2 epithelial cells. ISME Journal 2007 1 8 678 692 2-s2.0-36849052348 10.1038/ismej.2007.54 (Pubitemid 350231337)
20. Tsung K., Norton J. A., Lessons from Coley's Toxin. Surgical Oncology 2006 15 1 25 28 2-s2.0-33747873283 10.1016/j.suronc.2006.05.002 (Pubitemid 44293389)
21. Friedman H., Blanchard D. K., Newton C., Klein T., Stewart W., Keler T., Nowotny A., Distinctive immunomodulatory effects of endotoxin and nontoxic lipopolysaccharide derivatives in lymphoid cell cultures. Journal of Biological Response Modifiers 1987 6 6 664 677 2-s2.0-0023619393 (Pubitemid 17166300)
22. Park J. M., Fisher D. E., Testimony from the Bedside: from Coley's Toxins to Targeted Immunotherapy. Cancer Cell 2010 18 1 9 10 2-s2.0-77954249068 10.1016/j.ccr.2010.06.010
23. Thomas J. A., Badini M., The role of innate immunity in spontaneous regression of cancer. Indian Journal of Cancer 2011 48 2 246 251 2-s2.0-84860503128 10.4103/0019-509X.82887
24. Mason K. A., Hunter N. R., CpG plus radiotherapy: a review of preclinical works leading to clinical trial. Frontiers in Oncology 2012 2 101
25. Ursu R., Carpentier A. F., Immunotherapeutic approach with oligodeoxynucleotides containing CpG motifs (CpG-ODN) in malignant glioma. Advances in Experimental Medicine and Biology 2012 746 95 108 10.1007/978-1-4614-3146-6-8
26. Zent C. S., Smith B. J., Ballas Z. K., Wooldridge J. E., Link B. K., Call T. G., Shanafelt T. D., Bowen D. A., Kay N. E., Witzig T. E., Weiner G. J., Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leukemia and Lymphoma 2012 53 2 211 217 2-s2.0-84863769805 10.3109/10428194.2011.608451
27. Xu D., Liu H., Komai-Koma M., Direct and indirect role of Toll-like receptors in T cell mediated immunity. Cellular & Molecular Immunology 2004 1 4 239 246 2-s2.0-20444382606
28. Brown J., Wang H., Hajishengallis G. N., Martin M., TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. Journal of Dental Research 2011 90 4 417 427 2-s2.0-79954577277 10.1177/0022034510381264
29. Itoh T., Satoh H., Isono N., Rikiishi H., Kumagai K., Mechanism of stimulation of T cells by Streptococcus pyogenes: isolation of a major mitogenic factor, cytoplasmic membrane-associated protein. Infection and Immunity 1992 60 8 3128 3135 2-s2.0-0026691719
30. Decker W. K., Safdar A., Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: coley's legacy revisited. Cytokine and Growth Factor Reviews 2009 20 4 271 281 2-s2.0-69249218860 10.1016/j.cytogfr.2009.07. 004
31. Makrilia N., Syrigos K. N., Saif M. W., Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Journal of the Pancreas 2011 12 4 351 354 2-s2.0-79960205464
32. Busch M., Wilkowski R., Schaffer M., Duhmke E., Combined chemotherapy, radiotherapy, and immunotherapy for pancreatic carcinoma-a case report. Advances in Therapy 2000 17 3 133 139 2-s2.0-0033827220 (Pubitemid 30660331)
33. McCarthy E. F., The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. The Iowa Orthopaedic Journal 2006 26 154 158 2-s2.0-33847190697
34. Corzo C. A., Cotter M. J., Cheng P., Cheng F., Kusmartsev S., Sotomayor E., Padhya T., McCaffrey T. V., McCaffrey J. C., Gabrilovich D. I., Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. Journal of Immunology 2009 182 9 5693 5701 2-s2.0-66949145484 10.4049/jimmunol.0900092
35. Zoglmeier C., Bauer H., Nörenberg D., Wedekind G., Bittner P., Sandholzer N., Rapp M., Anz D., Endres S., Bourquin C., CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clinical Cancer Research 2011 17 7 1765 1775 2-s2.0-79953300942 10.1158/1078-0432.CCR-10-2672
36. Fisch P., Malkovsky M., Braakman E., Sturm E., Bolhuis R. L. H., Prieve A., Sosman J. A., Lam V. A., Sondel P. M., γ / δ T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis. Journal of Experimental Medicine 1990 171 5 1567 1579 2-s2.0-0025330735 10.1084/jem.171.5.1567 (Pubitemid 20167551)
37. Mölne L., Corthay A., Holmdahl R., Tarkowski A., Role of gamma/delta T cell receptor-expressing lymphocytes in cutaneous infection caused by Staphylococcus aureus. Clinical and Experimental Immunology 2003 132 2 209 215 2-s2.0-0038216948 10.1046/j.1365-2249.2003.02151.x (Pubitemid 36560614)
38. + γ δ T Cell-mediated innate immune response against Listeria monocytogenes infection. European Journal of Immunology 2002 32 4 928 935 2-s2.0-0041468870 10.1002/1521-4141(200204)32: 4<928::AID-IMMU928>3.0.CO;2-I (Pubitemid 34428807)
39. Havas H. F., Axelrod R. S., Burns M. M., Murasko D., Goonewardene M., Clinical results and immunologic effects of a mixed bacterial vaccine in cancer patients. Medical Oncology and Tumor Pharmacotherapy 1993 10 4 145 158 2-s2.0-0027143731